Clinicopathological Impacts of Expression of Neuronal Markers in Lymphangioleiomyomatosis.
Journal
The American journal of surgical pathology
ISSN: 1532-0979
Titre abrégé: Am J Surg Pathol
Pays: United States
ID NLM: 7707904
Informations de publication
Date de publication:
01 Nov 2023
01 Nov 2023
Historique:
pubmed:
21
8
2023
medline:
21
8
2023
entrez:
21
8
2023
Statut:
ppublish
Résumé
Lymphangioleiomyomatosis (LAM) is a tuberous sclerosis complex (TSC)-associated tumor, characterized by the expression of neural crest lineages including neuronal markers. Neural crest cells can differentiate into multiple cell types that contribute to tissues associated with TSC-related tumors, and TSC-related tumors could be specifically associated with distinct neural crest subtypes. This study aimed to clarify the clinicopathological effects of expression of neuronal markers in LAM. Lung tissues from 40 patients with LAM (of whom 13, 1, and 26 had undergone lung transplantation, lobectomy, and partial lung resection, respectively) were immunohistochemically analyzed. All patients were women, and their median age was 36 years (range: 24-62 y). All patients who underwent lung transplantation or lobectomy were classified as LAM histologic score (LHS)-3, whereas those who underwent partial lung resection were classified as LHS-1. LAM cells expressed peripherin (65%), and neuron-specific βIII-tubulin (43%). A comparison of the early (LHS-1) and advanced (LHS-3) stages of LAM revealed that neuron-specific βIII-tubulin was significantly expressed in the early stage of LAM ( P = 0.0009). Neuron-specific βIII-tubulin-positive LAM was associated with younger age ( P < 0.0001), the coexistence of renal angiomyolipoma ( P = 0.027), and the absence of retroperitoneal LAM ( P = 0.045). Furthermore, based on the expression levels of immunohistochemical markers in LAM, 2 distinct clusters with different expression levels of neuronal markers were observed. Approximately 40% to 60% of patients with LAM expressed neuron-specific βIII-tubulin and peripherin. Neuronal expression may be associated with disease severity.
Identifiants
pubmed: 37599567
doi: 10.1097/PAS.0000000000002113
pii: 00000478-990000000-00221
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1252-1260Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.
Références
Hayashi T, Kumasaka T, Mitani K, et al. Prevalence of uterine and adnexal involvement in pulmonary lymphangioleiomyomatosis: A clinicopathologic study of 10 patients. Am J Surg Pathol. 2011;35:1776–1785.
Henske EP, McCormack FX. Lymphangioleiomyomatosis - a wolf in sheep’s clothing. J Clin Invest. 2012;122:3807–3816.
McCormack FX, Travis WD, Colby TV, et al. Lymphangioleiomyomatosis: Calling it what it is: a low-grade, destructive, metastasizing neoplasm. Am J Respir Crit Care Med. 2012;186:1210–1212.
McCarthy C, Gupta N, Johnson SR, et al. Lymphangioleiomyomatosis: Pathogenesis, clinical features, diagnosis, and management. Lancet Respir Med. 2021;9:1313–1327.
Smolarek TA, Wessner LL, McCormack FX, et al. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: Chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet. 1998;62:810–815.
Sekimoto Y, Suzuki K, Okura M, et al. Uncommon radiologic computed tomography appearances of the chest in patients with lymphangioleiomyomatosis. Sci Rep. 2021;11:7170.
Zhe X, Yang Y, Schuger L. Imbalanced plasminogen system in lymphangioleiomyomatosis: Potential role of serum response factor. Am J Respir Cell Mol Biol. 2005;32:28–34.
Di Marco F, Terraneo S, Dias OM, et al. Natural history of incidental sporadic and tuberous sclerosis complex associated lymphangioleiomyomatosis. Respir Med. 2020;168:105993.
Wong M. Mechanisms of epileptogenesis in tuberous sclerosis complex and related malformations of cortical development with abnormal glioneuronal proliferation. Epilepsia. 2008;49:8–21.
Delaney SP, Julian LM, Stanford WL. The neural crest lineage as a driver of disease heterogeneity in tuberous sclerosis complex and lymphangioleiomyomatosis. Front Cell Dev Biol. 2014;2:69.
Normand EA, Crandall SR, Thorn CA, et al. Temporal and mosaic Tsc1 deletion in the developing thalamus disrupts thalamocortical circuitry, neural function, and behavior. Neuron. 2013;78:895–909.
Prabhakar S, Goto J, Zhang X, et al. Stochastic model of Tsc1 lesions in mouse brain. PLoS One. 2013;8:e64224.
Henske EP, Scheithauer BW, Short MP, et al. Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am J Hum Genet. 1996;59:400–406.
Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A. 2000;97:6085–6090.
Crino PB, Aronica E, Baltuch G, Nathanson KL. Biallelic TSC gene inactivation in tuberous sclerosis complex. Neurology. 2010;74:1716–1723.
Qin W, Chan JA, Vinters HV, et al. Analysis of TSC cortical tubers by deep sequencing of TSC1, TSC2 and KRAS demonstrates that small second-hit mutations in these genes are rare events. Brain Pathol. 2010;20:1096–1105.
Tyburczy ME, Wang JA, Li S, et al. Sun exposure causes somatic second-hit mutations and angiofibroma development in tuberous sclerosis complex. Hum Mol Genet. 2014;23:2023–2029.
Guo M, Yu JJ, Perl AK, et al. Single-cell transcriptomic analysis identifies a unique pulmonary lymphangioleiomyomatosis cell. Am J Respir Crit Care Med. 2020;202:1373–1387.
Cho JH, Patel B, Bonala S, et al. Notch transactivates rheb to maintain the multipotency of TSC-null cells. Nat Commun. 2017;8:1848.
Matsui K, Beasley MB, Nelson WK, et al. Prognostic significance of pulmonary lymphangioleiomyomatosis histologic score. Am J Surg Pathol. 2001;25:479–484.
Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016;32:2847–2849.
Roach ES, Gomez MR, Northrup H. Tuberous sclerosis complex consensus conference: Revised clinical diagnostic criteria. J Child Neurol. 1998;13:624–628.
Hayashi T, Kumasaka T, Mitani K, et al. Bronchial involvement in advanced stage lymphangioleiomyomatosis: Histopathologic and molecular analyses. Hum Pathol. 2016;50:34–42.
Rolim I, Makupson M, Lovrenski A, et al. Cathepsin K is superior to HMB45 for the diagnosis of pulmonary lymphangioleiomyomatosis. Appl Immunohistochem Mol Morphol. 2021;30:108–112.